Effect of glucagon-like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta-analysis.

Ali A, Siddiqui AA, Usman MS, Shahid I, Khan MS, Perswani P

Clinical obesity23 Apr 2025Cited by 3 (Europe PMC)

PMID40265328PMCIDPMC12289403DOI10.1111/cob.70012PepBankPUB-40265328

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

2 results from studies that gave the peptide. 2 results from people.

01HumanSystematic reviewEfficacy outcome
In reviewed patients with obesity and diabetes, liraglutide below 2 mg once daily had SBP-reduction estimate -3.78 (reported interval -6.27 to -1.28); the original numerical reference and confidence level were unstated.
In plain wordsIn reviewed patients with obesity and diabetes, liraglutide below 2 mg daily showed blood-pressure reduction; the numerical comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure with liraglutide below 2 mg once daily
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
<2 mg once dailyAs given in this study (human).
Measurements
SBP estimate
−3.78
liraglutide below2 mg once daily; original reference unstated
Reported interval
−6.27 to −1.28
confidence level unstated
Source sentences
Summary
Among patients with diabetes, liraglutide < 2 mg OD showed the greatest reduction in SBP (-3.78 [-6.27; -1.28]), while efpeglenatide ≤ 6 mg QW showed the greatest reduction in SBP (-6.00 [-9.89; -2.11]) in patients without diabetes.
2 context sentences(design, population, supporting numbers)
Summary · context
MEDLINE and Cochrane were searched until January 2022 for randomized control trials (RCTs) on patients with obesity, evaluating the impact of semaglutide, liraglutide, efpeglenatide, or exenatide on SBP.
Summary · context
Separate analyses were done for trials with and without diabetes.
Report a problemFND-4026532807
02HumanSystematic reviewEfficacy outcome
In reviewed patients with obesity and diabetes, liraglutide below 2 mg once daily had the greatest SBP reduction among assessed drug-dose combinations; no ranking probability was reported.
In plain wordsIn reviewed patients with obesity and diabetes, liraglutide below 2 mg daily ranked greatest for blood-pressure reduction among drug-dose combinations.
Peptide
Liraglutide
Outcome
Not applicableSBP-reduction efficacy ranking with diabetes
Study
n: not reported in source
Comparator
Other GLP-1RA drug-dose combinations in participants with diabetes
Outcome group
Blood pressure · Cardiovascular
Studied dose
<2 mg once dailyAs given in this study (human).
Source sentences
Summary
Among patients with diabetes, liraglutide < 2 mg OD showed the greatest reduction in SBP (-3.78 [-6.27; -1.28]), while efpeglenatide ≤ 6 mg QW showed the greatest reduction in SBP (-6.00 [-9.89; -2.11]) in patients without diabetes.
2 context sentences(design, population, supporting numbers)
Summary · context
MEDLINE and Cochrane were searched until January 2022 for randomized control trials (RCTs) on patients with obesity, evaluating the impact of semaglutide, liraglutide, efpeglenatide, or exenatide on SBP.
Summary · context
Separate analyses were done for trials with and without diabetes.
Report a problemFND-4026532808

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed patients with obesity with or without diabetes, pooled GLP-1RAs including liraglutide lowered SBP (MD -3.14, reported interval -3.60 to -2.68); the original estimate reference was unstated.
In plain wordsIn reviewed patients with obesity, pooled GLP-1 drugs including liraglutide lowered blood pressure; the original comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure in all patients
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Measurements
SBP MD
−3.14
all patients; original reference unstated
Reported interval
−3.6 to −2.68
SBP MD; confidence level not stated
Source sentences
Summary
GLP-1RAs significantly lowered SBP for all patients (MD = -3.14 [-3.60; -2.68]).
2 context sentences(design, population, supporting numbers)
Summary · context
MEDLINE and Cochrane were searched until January 2022 for randomized control trials (RCTs) on patients with obesity, evaluating the impact of semaglutide, liraglutide, efpeglenatide, or exenatide on SBP.
Summary · context
Separate analyses were done for trials with and without diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4026532801
04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed patients with obesity with or without diabetes, pooled GLP-1RAs including semaglutide lowered SBP (MD -3.14, reported interval -3.60 to -2.68); the original estimate reference was unstated.
In plain wordsIn reviewed patients with obesity, pooled GLP-1 drugs including semaglutide lowered blood pressure; the original comparison was unspecified.
Peptide
Semaglutide
Outcome
DecreaseSystolic blood pressure in all patients
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Measurements
SBP MD
−3.14
all patients; original reference unstated
Reported interval
−3.6 to −2.68
SBP MD; confidence level not stated
Source sentences
Summary
GLP-1RAs significantly lowered SBP for all patients (MD = -3.14 [-3.60; -2.68]).
2 context sentences(design, population, supporting numbers)
Summary · context
MEDLINE and Cochrane were searched until January 2022 for randomized control trials (RCTs) on patients with obesity, evaluating the impact of semaglutide, liraglutide, efpeglenatide, or exenatide on SBP.
Summary · context
Separate analyses were done for trials with and without diabetes.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4026532802
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed obesity populations, pooled GLP-1RA SBP-reduction magnitude was greater without diabetes than with diabetes (reported estimates -3.80 [-4.24,-3.37] and -2.13 [-3.27,-1.00]); no native liraglutide difference coefficient was reported.
In plain wordsIn reviewed obesity populations, pooled GLP-1 drugs including liraglutide reduced blood pressure more without diabetes than with diabetes.
Peptide
Liraglutide
Outcome
IncreaseSBP-reduction magnitude by diabetes status
Study
n: not reported in source
Comparator
Participants with diabetes
Outcome group
Blood pressure · Cardiovascular
Measurements
SBP estimate without diabetes
−3.8
original effect reference unstated
Reported interval without diabetes
−4.24 to −3.37
confidence level unstated
SBP estimate with diabetes
−2.13
original effect reference unstated
Reported interval with diabetes
−3.27 to −1
confidence level unstated
Source sentences
Summary
Subgroup analysis showed a significantly greater difference in SBP reduction for patients without diabetes (-3.80 [-4.24; -3.37]) when compared with patients with diabetes (-2.13 [-3.27; -1.00]).
2 context sentences(design, population, supporting numbers)
Summary · context
MEDLINE and Cochrane were searched until January 2022 for randomized control trials (RCTs) on patients with obesity, evaluating the impact of semaglutide, liraglutide, efpeglenatide, or exenatide on SBP.
Summary · context
Separate analyses were done for trials with and without diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4026532803
06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed obesity populations, pooled GLP-1RA SBP-reduction magnitude was greater without diabetes than with diabetes (reported estimates -3.80 [-4.24,-3.37] and -2.13 [-3.27,-1.00]); no native semaglutide difference coefficient was reported.
In plain wordsIn reviewed obesity populations, pooled GLP-1 drugs including semaglutide reduced blood pressure more without diabetes than with diabetes.
Peptide
Semaglutide
Outcome
IncreaseSBP-reduction magnitude by diabetes status
Study
n: not reported in source
Comparator
Participants with diabetes
Outcome group
Blood pressure · Cardiovascular
Measurements
SBP estimate without diabetes
−3.8
original effect reference unstated
Reported interval without diabetes
−4.24 to −3.37
confidence level unstated
SBP estimate with diabetes
−2.13
original effect reference unstated
Reported interval with diabetes
−3.27 to −1
confidence level unstated
Source sentences
Summary
Subgroup analysis showed a significantly greater difference in SBP reduction for patients without diabetes (-3.80 [-4.24; -3.37]) when compared with patients with diabetes (-2.13 [-3.27; -1.00]).
2 context sentences(design, population, supporting numbers)
Summary · context
MEDLINE and Cochrane were searched until January 2022 for randomized control trials (RCTs) on patients with obesity, evaluating the impact of semaglutide, liraglutide, efpeglenatide, or exenatide on SBP.
Summary · context
Separate analyses were done for trials with and without diabetes.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4026532804
07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed patients with obesity and diabetes, pooled GLP-1RAs including liraglutide reduced SBP (reported estimate -2.13, interval -3.27 to -1.00); original reference and confidence level were unstated.
In plain wordsIn reviewed patients with obesity and diabetes, pooled GLP-1 drugs including liraglutide reduced blood pressure; the original comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure in patients with diabetes
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Measurements
SBP estimate
−2.13
with diabetes; original reference unstated
Reported interval
−3.27 to −1
confidence level unstated
Source sentences
Summary
Subgroup analysis showed a significantly greater difference in SBP reduction for patients without diabetes (-3.80 [-4.24; -3.37]) when compared with patients with diabetes (-2.13 [-3.27; -1.00]).
2 context sentences(design, population, supporting numbers)
Summary · context
MEDLINE and Cochrane were searched until January 2022 for randomized control trials (RCTs) on patients with obesity, evaluating the impact of semaglutide, liraglutide, efpeglenatide, or exenatide on SBP.
Summary · context
Separate analyses were done for trials with and without diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4026532805
08HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed patients with obesity and diabetes, pooled GLP-1RAs including semaglutide reduced SBP (reported estimate -2.13, interval -3.27 to -1.00); original reference and confidence level were unstated.
In plain wordsIn reviewed patients with obesity and diabetes, pooled GLP-1 drugs including semaglutide reduced blood pressure; the original comparison was unspecified.
Peptide
Semaglutide
Outcome
DecreaseSystolic blood pressure in patients with diabetes
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Measurements
SBP estimate
−2.13
with diabetes; original reference unstated
Reported interval
−3.27 to −1
confidence level unstated
Source sentences
Summary
Subgroup analysis showed a significantly greater difference in SBP reduction for patients without diabetes (-3.80 [-4.24; -3.37]) when compared with patients with diabetes (-2.13 [-3.27; -1.00]).
2 context sentences(design, population, supporting numbers)
Summary · context
MEDLINE and Cochrane were searched until January 2022 for randomized control trials (RCTs) on patients with obesity, evaluating the impact of semaglutide, liraglutide, efpeglenatide, or exenatide on SBP.
Summary · context
Separate analyses were done for trials with and without diabetes.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4026532806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
27 Oct 2026, 16:32 UTC
Study data updated · source update from Europe PMC
Version 3
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.